Septerna Inc (SEPN)
Septerna Inc. is a clinical-stage biotechnology company focused on discovering and developing oral small-molecule therapies that target G protein-coupled receptors (GPCRs). Its pipeline includes the PTH1R program for hypoparathyroidism, SEP-631 for chronic spontaneous urticaria and other mast cell-related diseases, and a TSHR program being studied for Graves’ disease and thyroid eye disease. The company also has a global collaboration and license agreement with Novo Nordisk to pursue multiple potential oral small-molecule therapies for metabolic-related diseases based on specified molecular targets. Septerna is also evaluating opportunities in neurology, women’s health, cardiovascular disease, and respiratory disease. Founded in 2019 and formerly known as GPCR NewCo, Inc., the company is headquartered in South San Francisco, California. Its common stock is listed on NASDAQ under the symbol SEPN.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-SEPN
|
$32.62
|
-1.4% Downside
|
Fair
|
$45
|
36.1% Upside
|
Undervalued
|
Great
|
—
|
—
|
—
|
0.0%
|
August 17, 2026
|
-41.4x
|
3.9x
|
20.6x
|
1.452 B
|
992.1 M
|
1.6%
|
51.3%
|
4.5
|
—
|
-296.7%
|
